Discover how Nrf2 regulates Cereblon expression and influences clinical response to lenalidomide and erythropoietin combination therapy in lower-risk MDS.
Discover how FBXO11 acts as a tumor suppressor in the transformation of MDS to secondary AML, with groundbreaking research revealing its critical role in blood cancer progression.